Waters Corporation has launched a the Xevo MRT P10 mass spectrometer, a high-resolution Quadrupole Time-of-Flight (QToF) system for high-throughput multiomics, bioanalysis and biopharmaceutical laboratories.
The Xevo MRT P10 MS is designed to accelerate iomarket discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies.
“By combining enhanced MS/MS sensitivity, the industry’s fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS – and layering in a new benchmark for MS imaging speed and throughput with our DESI XS – this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions,” said James Hallma, VP and MG, Liquid Chromatography-Mass Spectrometry Waters Analytical Sciences, Waters Corporation. “The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies.”
The spectrometer delivers up to 20x higher MS/MS sensitivity compared to its predecessor. Its speed and expanded acquisition modes support both targeted and untargeted analysis in a single benchtop platform.
In comparative lipid profiling by LC-MS/MS, the Xevo MRT P10 MS enabled identification of up to 40% more lipids than the most competitive alternative system.
The Xevo MRT P10 MS was showcased at ASMS 2026 and is expected to be available globally beginning summer 2026.
Earlier this year, Waters received EU approval for its BD Bactec FXI Culture System.
